Regulation of mitochondrial adenine nucleotide content in newborn rabbit liver.
This study examined the relationship between postnatal metabolic and hormonal changes and the accompanying rapid increase in mitochondrial adenine nucleotide content (ATP + ADP + AMP) in rabbit liver. The cytosolic NAD+/NADH concentration ratio, calculated from tissue pyruvate and lactate values, increased linearly 6.6-fold during the 1st postnatal h. The mitochondrial NAD+/NADH concentration ratio, calculated from tissue acetoacetate and beta-hydroxybutyrate values, increased 28-fold by 30 min postnatal. These changes in NAD+/NADH suggest that tissue oxygenation occurs rapidly and that oxygen supply rather than substrate supply is limiting for mitochondrial respiration in the immediate postnatal period. The normal increase in mitochondrial adenine nucleotide content that occurs within 2 h after birth was inhibited by hypoxia (5% O2). Glucagon stimulated the postnatal increase in mitochondrial adenine nucleotides but had no effect in combination with hypoxia. Both glucose and somatostatin injections inhibited the increase in mitochondrial adenine nucleotides and increased the insulin-to-glucagon ratio. Isoproterenol or dibutyryl cAMP stimulated, but propranolol did not inhibit, the normal increase in mitochondrial adenine nucleotide content. Phentolamine did not stimulate the postnatal accumulation of adenine nucleotides. In summary, the results show that the insulin-to-glucagon ratio is probably the most important hormone regulator of the rapid recompartmentation of adenine nucleotides into the mitochondrial matrix and that tissue oxygenation is strictly permissive for this hormone effect in the first 2 h after birth.
D020155:3-Hydroxybutyric Acid; D000090:Acetoacetates / Q000378:metabolism; D000227:Adenine Nucleotides / Q000378:metabolism*; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn / Q000378:metabolism*; D003994:Bucladesine / Q000494:pharmacology; D003600:Cytosol / Q000378:metabolism; D005934:Glucagon / Q000494:pharmacology; D005947:Glucose / Q000494:pharmacology; D006885:Hydroxybutyrates / Q000378:metabolism; D007328:Insulin / Q000502:physiology; D007545:Isoproterenol / Q000494:pharmacology; D007700:Kinetics; D007773:Lactates / Q000378:metabolism; D019344:Lactic Acid; D008930:Mitochondria, Liver / Q000187:drug effects / Q000378:metabolism*; D009243:NAD / Q000378:metabolism; D010084:Oxidation-Reduction; D010100:Oxygen / Q000502:physiology; D011773:Pyruvates / Q000378:metabolism; D019289:Pyruvic Acid; D011817:Rabbits
D000090:Acetoacetates; D000227:Adenine Nucleotides; D000318:Adrenergic beta-Agonists; D006885:Hydroxybutyrates; D007328:Insulin; D007773:Lactates; D011773:Pyruvates; D009243:NAD; D019344:Lactic Acid; C016635:acetoacetic acid; D003994:Bucladesine; D019289:Pyruvic Acid; D005934:Glucagon; D005947:Glucose; D007545:Isoproterenol; D010100:Oxygen; D020155:3-Hydroxybutyric Acid